Health Kick: Prescient Therapeutics’ YTD share price soars +220% after progress in clinical studies and CAR-T platform
Stockhead’s resident health and biotech expert Tim Boreham is putting down the microscope and picking up...
Stockhead’s resident health and biotech expert Tim Boreham is putting down the microscope and picking up...
The appointment gives PTX a world-leading development team in the race to find solutions for...
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has appointed brain cancer specialist Professor Donald O’Rourke to...
Researchers at the University of Pennsylvania (Penn) are developing a new way for cancer-fighting CAR-T...
Prescient Therapeutics (ASX: PTX) Managing Director and Chief Executive Officer Steven Yatomi-Clarke joins Small Caps...
CAR-T therapies have proven to be revolutionary treatments for cancer, but their high costs have...
Got 90 seconds? Then listen to CEO, Steven Yatomi-Clarke tell us about their company news....
Clinical-stage oncology company Prescient Therapeutics’ (ASX: PTX) strong cash position will enable it to advance its multiple...
ASX-listed oncology player Prescient Therapeutics Limited (ASX:PTX) is engaged in developing a robust drug pipeline...
Clinical-stage oncology firm Prescient Therapeutics Limited (ASX:PTX) has announced its June 2021 results, marked by...
This investor centre was built by Reach Markets
©2025 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.